{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aclidinium+Bromide", "query": { "intervention": "Aclidinium Bromide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aclidinium+Bromide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T14:07:03.997Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01437540", "title": "Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium Bromide/Formoterol Fumarate", "type": "DRUG" }, { "name": "Formoterol Fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 590, "start_date": "2011-09-19", "completion_date": "2013-04-30", "has_results": true, "last_update_posted_date": "2017-05-11", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 137, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 110 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01437540" }, { "nct_id": "NCT01044459", "title": "Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium Bromide 200 µg", "type": "DRUG" }, { "name": "Aclidinium Bromide 400 µg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 605, "start_date": "2009-11", "completion_date": "2011-04", "has_results": true, "last_update_posted_date": "2017-04-20", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 110, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 93 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01044459" }, { "nct_id": "NCT00500318", "title": "A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "Aclidinium Bromide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 181, "start_date": "2007-07", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2017-01-06", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 42, "location_summary": "Jasper, Alabama • Phoenix, Arizona • Long Beach, California + 33 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00500318" }, { "nct_id": "NCT01049360", "title": "Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium 400 μg / Formoterol 12 μg", "type": "DRUG" }, { "name": "Aclidinium 400 μg / Formoterol 6 μg", "type": "DRUG" }, { "name": "Aclidinium 400 μg", "type": "DRUG" }, { "name": "Formoterol 12 μg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 128, "start_date": "2009-12", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2017-02-28", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 20, "location_summary": "Glendale, Arizona • Pheonix, Arizona • Rancho Mirage, California + 16 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Pheonix", "state": "Arizona" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01049360" }, { "nct_id": "NCT02796677", "title": "AMPLIFY - D6571C00001 Duaklir USA Phase III Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)", "type": "DRUG" }, { "name": "Aclidinium bromide 400 μg (AB 400 μg)", "type": "DRUG" }, { "name": "Formoterol fumarate 12 μg (FF 12 μg)", "type": "DRUG" }, { "name": "Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg", "type": "OTHER" }, { "name": "Tiotropium 18 μg (TIO 18 μg)", "type": "DRUG" }, { "name": "Placebo to TIO 18 μg", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "40 Years to 130 Years" }, "enrollment_count": 1595, "start_date": "2016-07-05", "completion_date": "2017-06-08", "has_results": true, "last_update_posted_date": "2018-11-09", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 85, "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more", "locations": [ { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02796677" }, { "nct_id": "NCT01551888", "title": "Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "Aclidinium/formoterol 400/12μg", "type": "DRUG" }, { "name": "Formoterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 24, "start_date": "2012-01", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-02-14", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 1, "location_summary": "Spartanburg, South Carolina", "locations": [ { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01551888" }, { "nct_id": "NCT05457868", "title": "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Salbutamol", "type": "DRUG" }, { "name": "LAMA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 124117, "start_date": "2021-02-01", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05457868" }, { "nct_id": "NCT00891462", "title": "Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium bromide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 561, "start_date": "2009-04", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2017-01-06", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 104, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891462" }, { "nct_id": "NCT00358436", "title": "Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "Aclidinium bromide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 804, "start_date": "2006-08", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 73, "location_summary": "Jasper, Alabama • Ozark, Alabama • Phoenix, Arizona + 64 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Ozark", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00358436" }, { "nct_id": "NCT01437397", "title": "Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium Bromide/Formoterol Fumarate", "type": "DRUG" }, { "name": "Aclidinium Bromide", "type": "DRUG" }, { "name": "Formoterol Fumarate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1692, "start_date": "2011-09", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-09-16T14:07:03.997Z", "location_count": 193, "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 155 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01437397" } ] }